Jelmyto Treatment for Upper Tract Urothelial Cancer
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Recruiting
Observational Study
Urothelial CarcinomaUrothelial Carcinoma RecurrentUrothelial Carcinoma UreterUrothelial Carcinoma Ureter RecurrentUrothelial Cancer of Renal PelvisUrothelial Carcinoma of the Renal Pelvis and UreterCarcinoma, Transitional CellTransitional Cell Carcinoma of Renal Pelvis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
450 (estimated)
Sponsor
UroGen Pharma Ltd. · Industry
Who this trial is looking for
This trial is looking for adults with Upper Tract Urothelial Cancer who have received Jelmyto after it was approved by the FDA. Participants will help researchers understand the outcomes of this treatment in real-world situations.
Are You a Good Fit for This Trial?
You may be able to join if
I am over 18 years old.
I have been diagnosed with Upper Tract Urothelial Cancer.
I have received at least one dose of Jelmyto after April 15, 2020.
You may not be able to join if
I cannot give informed consent.
I received Jelmyto before April 15, 2020.
I am pregnant or breastfeeding.
I cannot follow the trial's requirements.
I have a medical or mental condition that my doctor thinks makes it unsafe for me to participate.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Adults \>18 years old and capable of giving informed consent.
* Diagnosis of UTUC.
* Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).
Exclusion Criteria:
* Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia)…
Inclusion Criteria:
* Adults \>18 years old and capable of giving informed consent.
* Diagnosis of UTUC.
* Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).
Exclusion Criteria:
* Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).
* Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).
* Pregnancy or lactation.
* Unable to comply with protocol requirements (for prospective data capture).
* Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
